Dietary supplement supporting reduction of estrogen levels and estrogen and progesterone receptors

PL450957A1Pending Publication Date: 2026-07-20ESTABLO PHARMA SP ZOO

Patent Information

Authority / Receiving Office
PL · PL
Patent Type
Applications
Current Assignee / Owner
ESTABLO PHARMA SP ZOO
Filing Date
2025-01-15
Publication Date
2026-07-20
Patent Text Reader

Abstract

The subject of the application is a dietary supplement containing 2.5 - 7 wt.% indole-3-carbinol, 2 - 6 wt.% epigallocatechin gallate, 30 - 70 wt.% myo-inositol, 6 - 12.5 wt.% N-acetylcysteine, 2.5 - 7 wt.% quercetin, 5 - 8.5 wt.% Omega-3 acid, 5 - 8.5 wt.% alphalipoic acid, 2 - 6 wt.% vitamin C, 1 - 5 wt.% resveratrol, 0.01 - 0.2 wt.% vitamin D3, 0.5 - 3.5 wt.% vitamin E, 0.2 - 15 wt.% alpha-lactalbumin, 0.04 - 20 wt.% curcumin, 0.2 – 15% w / w D-chiroinositol, 0.2- 24% w / w inulin, a probiotic consisting of a mixture of strains of the Lactobacillus, Bifidobacterium and Saccharomyces genera for patients with reproductive system diseases supporting the reduction of estrogen levels and estrogen and progesterone receptors.
Need to check novelty before this filing date? Find Prior Art